Vascular Disease and Risk Factors,Rate of Progression,and Survival in Alzheimer’s Disease

Abstract

Two hundred forty-seven patients with early Alzheimer’s disease were studied for the association of demographic, functional, and cognitive status and vascular comorbidities and risk factors present at index visit to rate of clinical disease progression over 3 years and to survival time. Patients who progressed to the moderate stage were designated fast progressors; those who remained in the early stage were designated slow progressors. At index visit, Mini-Mental State Exam score was significantly lower for the fast than the slow group; global impairment was significantly higher for the fast group. Cognitive scores showed greater annual decline in the fast group, and the fast group also had a greater annualized global change. The fast group had a shorter median survival time from onset, but age at onset, age at initial visit, history of heart problems, myocardial infarct, stroke, hypertension, diabetes, or past or current smoking did not differ between groups.

Keywords

Alzheimer vascular risk factors vascular comorbidity

Get full access to this article

View all access options for this article.

References

Sparks DL.

Coronary artery disease, hypertension, apoE, and cholesterol: a link to Alzheimer’s disease?

Ann NY Acad Sci 1997; 826:128-146.

Skoog I , Lernfelt B , Landahl S , et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.

Kivipelto M , Helkala E-L , Laakso MP , et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322:1447-1451.

Launer LJ , Ross GW , Petrovitch H , et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21:49-55.

Forette Forette F , Seux ML , Staessen JA , et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Int Med 2002; 162:2046-2052.

Peila R , Rodriguez BL , Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies. Diabetes 2002; 51:1256-1262.

Luchsinger JA , Tang MX , Stern Y , et al. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154:635-641.

Honig LS , Kukull W , Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer’s Coordinating Center. Neurology 2005; 64:494-500.

Ambrose JA , Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43:1731-1737.

10.

Lu JT , Creager MA. The relationship of cigarette smoking to peripheral arterial disease. Rev Cardiovasc Med 2004; 5:189-193.

11.

Weiner MF , Vega G , Risser RC , et al. Apolipoprotein Eε4, other risk factors, and course of Alzheimer’s disease. Biol Psychiatry 1999; 45:633-638.

12.

Hoyt BD , Massman PJ , Schatschneider C , et al. Individual growth curve analysis of APOE ε4-associated cognitive decline in Alzheimer’s disease. Arch Neurol 2005; 62:454-459.

13.

McKhann G , Drachman D , Folstein M , et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34:939-944.

14.

Hughes CP , Berg L , Danziger WL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-572.

15.

Folstein MF , Folstein SE , McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.

16.

Irina A , Seppo H , Arto M , et al. ß-amyloid load is not influenced by the severity of cardiovascular disease in aged and demented patients. Stroke 1999; 30:613-618.

17.

Morris JC , Edland S , Clark C , et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer’s disease. Neurology 1993; 43: 2457-2465.

18.

Doody RS , Massman P , Dunn JK. A method for estimating progression rates in Alzheimer disease. Arch Neurology 2001; 58:449-454.

19.

Hui JS , Wilson RS , Bennett DA , et al. Rate of cognitive decline and mortality in Alzheimer’s disease. Neurology 2003; 61:1356-1361.